Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 27
- Registration Number
- NCT06001658
- Locations
- 🇺🇸
SKCCC Johns Hopkins, Baltimore, Maryland, United States
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 25
- Registration Number
- NCT05996484
Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT05978609
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 64
- Registration Number
- NCT05975307
- Locations
- 🇨🇳
Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05967182
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT05945823
- Locations
- 🇺🇸
University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States
🇺🇸Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Pembrolizumab in Locally Advanced Sinonasal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Target Recruit Count
- 28
- Registration Number
- NCT05925491
- Locations
- 🇮🇹
Istituti Clinici Scientifici Maugeri, Pavia, Lombardia, Italy
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Renmin Hospital of Wuhan University
- Target Recruit Count
- 155
- Registration Number
- NCT05919030
- Locations
- 🇨🇳
Renmin hosptial of Wuhan University, Wuhan, Hubei, China
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT05918107
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT05911295
- Locations
- 🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇧🇷Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Other, Brazil
🇧🇷Centro de Oncologia da Bahia, Salvador, Other, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.